🇺🇸 FDA
Patent

US 10973894

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

granted A61KA61K2039/5158A61K2239/38

Quick answer

US patent 10973894 (Methods of isolating T cells having antigenic specificity for a cancer-specific mutation) held by The United States of America, as represented by the Secretary, Department of Health and Human expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human
Grant date
Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/5158, A61K2239/38, A61K39/0011, A61K40/11